Eli Lilly's New Weight Loss Drug Zepbound Rapidly Gaining Sales and Wall Street Attention

Eli Lilly's new weight loss drug Zepbound, based on the diabetes drug Mounjaro, is outperforming rival Novo Nordisk's Wegovy in sales growth.

Zepbound acts on both GLP-1 and GIP receptors, giving it better efficacy in weight loss compared to Wegovy.

Wall Street analysts predict Zepbound could reach $50-69 billion in peak annual sales.

Eli Lilly partners with Amazon Pharmacy for direct shipping of treatments like Zepbound.

Despite strong growth prospects, Eli Lilly stock may be overvalued trading at 63x 2024 earnings estimates.